<DOC>
	<DOC>NCT02722265</DOC>
	<brief_summary>To examine antihypertensive effect, pharmacodynamics, and safety of long-term administration of CS-3150 as monotherapy and in combination with calcium channel blocker or renin-angiotensin system inhibitor in patients with essential hypertension.</brief_summary>
	<brief_title>Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<criteria>Male and female subjects aged 20 years or older at informed consent Subjects with essential hypertension, who do not receive any antihypertensive drugs or receive calcium channel blocker, angiotensin converting enzyme ACE inhibitor, or angiotensinII receptor blockade ARB during runin period (Sitting systolic blood pressure SBP ≥ 140 mmHg and &lt; 180 mmHg, Sitting diastolic blood pressure DBP ≥ 90 mmHg and &lt; 110 mmHg, and mean 24hr SBP ≥ 130 and DBP ≥ 80 mmHg) Secondary hypertension or malignant hypertension Diabetes mellitus with albuminuria Serum potassium level &lt; 3.5 or ≥ 5.1 mEq/L (≥ 4.8 mEq/L if receive ACE inhibitor, or ARB) Reversed daynight life cycle including overnight workers estimated glomerular filtration rate eGFR &lt; 60 mL/min/1.73 m^2.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Essential hypertension</keyword>
	<keyword>Long-term treatment</keyword>
	<keyword>Mineralocorticoid receptor antagonist</keyword>
</DOC>